TOKYO – China's government and drug regulator is moving toward internationalization. And while the push may seem slow, the sheer number of reforms under way may be difficult to stay on top of for multinationals.
TOKYO – Harmonizing the regulatory environment across Asia and making it easier to get drugs to the market should be the priority for government agencies across the continent, said participants at the Drug Information Association’s Asia New Drug Conference Wednesday.
TOKYO – News that Japanese pharma Daiichi Sankyo Group is pinning its growth strategy on oncology followed on the heels of the announcement that Daiichi and partner, U.S. firm Arqule Inc., are advancing their METIV-HCC study for tivantinib after achieving 60 percent of the target number of 500 patients with MET-high tumors in December.
TOKYO – News that Japanese pharma Daiichi Sankyo Group is pinning its growth strategy on oncology followed on the heels of the announcement that Daiichi and partner, U.S. firm Arqule Inc., are advancing their METIV-HCC study for tivantinib after achieving 60 percent of the target number of 500 patients with MET-high tumors in December,
TOKYO – Japan has made great strides in speeding drug and device approvals, but there are concerns that fewer products are coming to market despite the visible regulatory improvements over the past decade.
TOKYO – Japan has made great strides in speeding drug and device approvals, but there are concerns that fewer products are coming to market despite the visible regulatory improvements over the past decade.
